Connie Marras, MD, PhD, of the University of Toronto (Canada) will work to validate a well-known test for cognitive impairment, the Montreal Cognitive Assessment (MoCA), for diagnosing PD-related cognitive changes. Currently available tests for detecting cognitive impairment are either insensitive to the specific changes that occur in PD, test only some of the brain functions that can be impaired in PD-related dementia, and/or can be highly time-consuming. The MoCA, which takes less than 10 minutes to administer, could offer a wider window for detecting changes in PD patients. Dr. Marras will enroll 140 PD patients to take the MoCA questionnaire, whom she will then follow over time to determine the ability of MoCA to detect cognitive impairment in PD. Validation of the MoCA will provide a critical research tool needed to improve diagnosis of PD cognitive changes as well as for testing of novel therapeutics in future clinical trials.
Celeste Napier, PhD, of Rush University (USA) will work to shed light
on the pathological gambling and other problems with impulse control that
may be linked to dopamine replacement therapy in PD. While dopamine is
involved with both the motor and reward systems, it is unclear why some PD
patients exhibit reward-seeking behavior
|SOURCE EMD Serono, Inc.|
Copyright©2008 PR Newswire.
All rights reserved